^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HLA-A*03

    i
    Other names: HLA-A, Major Histocompatibility Complex, Class I, A, HLA Class I Histocompatibility Antigen, A Alpha Chain, HLAA, HLA Class I Histocompatibility Antigen, A-1 Alpha Chain, MHC Class I Antigen HLA-A Heavy Chain, Leukocyte Antigen Class I-A, Human Leukocyte Antigen A
    Entrez ID:
    3105
    Related biomarkers:
    Expression
    Mutation
    Others
    8ms
    DC Vaccine in Pancreatic Cancer (clinicaltrials.gov)
    P1, N=29, Completed, University of Pennsylvania | Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Feb 2024 | Trial primary completion date: Sep 2024 --> Feb 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02 • HLA-A*11
    10ms
    Genomic profiles and their relationships with clinical characteristics and immune features in cervical cancer. (PubMed, Transl Oncol)
    This study offers insights into the mutation characteristics of cervical cancer patients and identifies potential therapeutic.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • NOTCH1 (Notch 1) • PD-1 (Programmed cell death 1) • KMT2D (Lysine Methyltransferase 2D) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • BARD1 (BRCA1 Associated RING Domain 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • CEP290 (Centrosomal Protein 290) • SLX4 (SLX4 Structure-Specific Endonuclease Subunit)
    |
    TMB-L • KMT2D mutation • HLA-A*03 • BARD1 mutation
    1year
    DC Vaccine in Pancreatic Cancer (clinicaltrials.gov)
    P1, N=29, Active, not recruiting, University of Pennsylvania | N=12 --> 29
    Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase) • HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02 • HLA-A*11
    1year
    DC Vaccine in Pancreatic Cancer (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KRAS (KRAS proto-oncogene GTPase) • HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02 • HLA-A*11
    1year
    DC Vaccine in Pancreatic Cancer (clinicaltrials.gov)
    P1, N=12, Recruiting, University of Pennsylvania | Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02
    over1year
    The germline HLA-A02B62 supertype is associated with a PD-L1-positive tumour immune microenvironment and poor prognosis in stage I lung cancer. (PubMed, Heliyon)
    The HLA-A02B62 supertype could serve as a possible indicator of poor prognosis in early-stage lung cancer. However, it may also act as a favorable prognostic factor for immunotherapy, given its association with a PD-L1-positive tumour microenvironment.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A) • CD68 (CD68 Molecule) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    PD-L1 expression • HLA-A*03 • HLA-A*02
    over1year
    Patient-specific HLA-I genotypes predict response to immune checkpoint blockade (ESMO 2023)
    Conclusions HLA-A status predicted clinical outcomes of patients receiving ICB. HLA genotyping could be incorporated early into the diagnostic work-up of patients with solid cancers as a predictive and selective biomarker.
    Clinical • Checkpoint inhibition • Checkpoint block
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*03 • HLA-A*02:01 • HLA-A*02 • HLA-A2 positive
    over1year
    DC Vaccine in Pancreatic Cancer (clinicaltrials.gov)
    P1, N=12, Recruiting, University of Pennsylvania | Trial completion date: Mar 2023 --> Sep 2023 | Trial primary completion date: Mar 2023 --> Sep 2023
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02
    almost2years
    Depicting ONC201/Delta-24-RGD combination for the treatment of pHGGs and DMGs reveals a therapeutic benefit and a proinflammatory tumor microenvironment remodelation (AACR 2023)
    Our data support the combination ONC201/Delta-24-RGD leads to a superior therapeutic effect due to the generation of a proinflammatory microenvironment in pHGG and DMGs preclinical models.
    IO biomarker
    |
    ATF4 (Activating Transcription Factor 4)
    |
    HLA-A*03
    |
    dordaviprone (ONC201)
    2years
    DC Vaccine in Pancreatic Cancer (clinicaltrials.gov)
    P1, N=12, Recruiting, University of Pennsylvania | Trial completion date: Sep 2022 --> Mar 2023 | Trial primary completion date: Sep 2022 --> Mar 2023
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02
    2years
    The variation of T-Cell receptors (TCR) diversity and genomic Human Leukocyte Antigen (HLA-I) among non-small cell lung cancer (NSCLC) patients expressing high PDL-1 (>=50%) versus those with low or no PDL1 (<50%). (SITC 2022)
    2013-246 and RGS0000003289) in compliance with the Declaration of Helsinki. Consent All participants signed a consent form which is saved at ECU research database.
    Clinical
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HLA-A*03 • PD-1-L
    over2years
    The variation of T cell receptor (TCR) diversity and genomic human leukocyte antigen-I (HLA-I) among non-small cell lung cancer (NSCLC) patients expressing high PDL1 versus those with low or no PDL1 (ESMO 2022)
    Conclusions Here we report that high PDL1 NSCLC are associated with distinct pre-treatment TCR repertoire and HLA-I supertypes comparing to low PDL1. Mechanistic studies are required to understand the biology of different types of NSCLC and hence have positive influence on treatment personalisation.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HLA-A*03 • PD-1-L
    over2years
    Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab. (PubMed, Cancer Sci)
    However, their impact on treatment response is limited, and germline HLA genotypes was not independently associated with survival outcomes. Further prospective studies are needed to confirm the relationship between germline HLA genotypes and clinical outcomes in patients with chemoresistant advanced UC treated with pembrolizumab.
    Clinical data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1)
    |
    HLA-A*03 • HLA-DQB1*03:01
    |
    Keytruda (pembrolizumab)
    over2years
    DC Vaccine in Pancreatic Cancer (clinicaltrials.gov)
    P1, N=12, Recruiting, University of Pennsylvania | Trial completion date: Mar 2022 --> Sep 2022 | Trial primary completion date: Mar 2022 --> Sep 2022
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02
    almost3years
    HLA-I homozygosity as a protective biomarker for developing immune related adverse events (irAE) among non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy in the first- or second-line setting (AACR 2022)
    Homozygosity at one or more HLA-I loci can be a useful biomarker to predict irAE among NSCLC patients treated with anti-PD1/PD-L1 in the first- or second-line setting. This is more important among patients who developed pneumonitis or Grade 3 toxicities. However, the occurrence of any irAE is correlated with favourable clinical outcome.
    Clinical • Adverse events • PD(L)-1 Biomarker • IO biomarker
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1)
    |
    HLA-A*03 • HLA-DQB1*03:01
    almost3years
    KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer. (PubMed, Front Immunol)
    Indeed, patients with tel B haplotype without KIR3DL2/HLA-A03 or A11 showed a better outcome. Our data, although preliminary, suggested a potential predictive role for KIR haplotype tel B, in identifying patients who achieve a pCR after neoadjuvant treatment with trastuzumab, and supported a negative prognostic impact of KIR3DL2/HLA-A03 or A11 in the adjuvant setting.
    Clinical Trial,Phase II • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2) • FCGR3A (Fc Fragment Of IgG Receptor IIIa)
    |
    HER-2 positive • HLA-A*03
    |
    Herceptin (trastuzumab)
    3years
    DC Vaccine in Pancreatic Cancer (clinicaltrials.gov)
    P1, N=12, Recruiting, University of Pennsylvania | Trial completion date: Oct 2021 --> Mar 2022 | Trial primary completion date: Oct 2021 --> Mar 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02